Clinical trials: Levodopa
Parkinson's Disease
A Phase 2b Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa
The purpose of this study is to establish the efficacy of 20 mg/day and 40 mg/day doses of istradefylline for reducing the mean total hours of awake time per day spent in the OFF state in patients with advanced Parkinson's…
- Trial name
- NCT00455507
- Testing
- Istradefylline
- Where
- Japan
- Volunteers
- 363 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Parkinson's Disease
A Long-Term, Safety Study With a Flexible Dose Range of KW-6002 in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy
The primary objective of this study was to establish the long-term tolerability and safety of istradefylline treatment in subjects with Parkinson's disease treated with levodopa/carbidopa.
- Trial name
- NCT00955045
- Testing
- istradefylline
- Where
- United States
- Sponsor
- Kyowa Kirin, Inc.
Parkinson's Disease
Gastric Retentive Carbidopa/ Levodopa in Parkinson's Patients; a One Year, Open Label, Safety Extension Study
An extension of study IN 09 004 testing the long term safety of the Accordion Pill Carbidopa/Levodopa (AP-CD/LD)
- Trial name
- NCT00947037
- Testing
- AP-CD/LD
- Where
- 5 sites in Israel
- Sponsor
- Intec Pharma Ltd.
Parkinson's Disease
Long-Term Safety Study of KW-6002 (Istradefylline) in Parkinson's Disease Patients
Patients with Parkinson's disease who completed the prior double-blind study 6002-009 are eligible to enter into this long-term study.
- Trial name
- 6002-010 (NCT00957203)
- Testing
- Istradefylline
- Where
- Japan
- Volunteers
- 308 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Parkinson Disease
WD-1603 PK Study Under Fasting and Fed Conditions in Healthy Subjects
The Phase 1 PK study is planned to evaluate the food effect on WD-1603 pharmacokinetics
- Trial name
- NCT04513340
- Testing
- WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS
- Where
- India
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Hong Kong WD Pharmaceutical Co., Limited
Parkinson's Disease, Levodopa Induced Dyskinesias (LID)
Efficacy and Safety of Amantadine Hydrochloride (HCl) ER Tablets to Treat Parkinson's Disease Patients With LID.
This study was terminated early due to slow enrollment with 87 of 162 planned subjects enrolled. The purpose of this multi-center, randomized, double-blind, parallel-group, 16 week study is to compare the efficacy and safety of…
- Trial name
- ALLAY-LID-I (NCT02153645)
- Testing
- 240mg Amantadine HCl ER tablets, 320mg Amantadine HCl ER tablets
- Where
- 56 sites in United States, Canada and 3 more
- Volunteers
- 87 people
- Sponsor
- Adamas Pharmaceuticals, Inc.
Idiopathic Parkinson's Disease
A Study to Assess the Effect of Safinamide on Levodopa Pharmacokinetics
The objective of this study is to investigate the effect of safinamide on levodopa blood levels, both after single and multiple dosing of safinamide .
- Trial name
- NCT01026428
- Testing
- Safinamide + Levodopa
- Where
- 2 sites in Italy
- Volunteers
- 24 people
- Sponsor
- Newron Pharmaceuticals SPA
Parkinson Disease
Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in patients with a diagnosis of Parkinson's Disease consistent with the UK Parkinson's Disease Society (UKPDS) Brain Bank…
- Trial name
- NCT05766813
- Testing
- Lenrispodun
- Where
- 35 sites in United States
- Volunteers
- 79 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Parkinson's Disease
Kinesia HomeView - Home Diary Comparison
The objective is to compare the sensitivity and test-retest reliability of Kinesia HomeView to electronic and hand-written diaries for tracking medication state in the home.
- Trial name
- NCT01920425
- Testing
- Kinesia HomeView, Hand-written diary
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Great Lakes NeuroTechnologies Inc.
Parkinson's Disease (PD)
The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics
The purpose of this study is to determine the effect of repeated dosing of once-daily 25, 50 and 75 mg opicapone (OPC, development code BIA 9-1067) on the levodopa pharmacokinetics (PK), in comparison to placebo and 200 mg…
- Trial name
- NCT02170376
- Testing
- BIA 9-1067, Entacapone, Levodopa/carbidopa
- Where
- France
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Idiopathic Parkinson Disease
Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)
This is a Phase IV, prospective, observational, post-marketing study designed to obtain additional data on the effect of XADAGO on motor and non-motor symptoms in Parkinson's Disease patients newly prescribed XADAGO.
- Trial name
- PRO-Go (NCT03944785)
- Testing
- XADAGO (safinamide)
- Where
- 30 sites in United States
- Volunteers
- 164 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Healhty
A Study to Assess Effect of Dosing Intervals on Multiple-Dose Pharmacokinetics of WD-1603 Taken Before Meals in Healthy Participants
WD-1603 contains two different drugs called levodopa and carbidopa in one tablet. The goal of this clinical trial is to see if taking the study drug WD-1603 at different time intervals affects how the drug acts in healthy…
- Trial name
- NCT07442591
- Testing
- Carbidopa and Levodopa Controlled-Release Tablets (25 mg/150 mg)
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Shanghai WD Pharmaceutical Co., Ltd.
Parkinson's Disease
A Long-Term Extension Trial From of SPM 962 in Advanced Parkinson's Disease Patients
To investigate the safety of once-daily repeated transdermal administration of SPM 962 within a dose range of 4.5 to 36.0 mg/day (54-week treatment period) in Parkinson's disease (PD) patients treated concomitantly with L-dopa in…
- Trial name
- NCT01631825
- Testing
- SPM 962
- Where
- 8 sites in Japan
- Volunteers
- 321 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Dyskinesia, Drug-Induced, Parkinson Disease
Safinamide for Levodopa-induced Dyskinesia (PD-LID)
This will be a prospective, multi-center, randomized, double-blind, parallel group, placebo-controlled study, in participants with PD who are on a stable regimen of dopaminergic medication and have at least mild levodopa-induced…
- Trial name
- NCT03987750
- Testing
- Safinamide Methanesulfonate 150mg, Safinamide Methanesulfonate 100mg
- Sponsor
- Zambon SpA
Parkinson's Disease
The Effect Of E2007 On Pharmacodynamic Responses To Levodopa Among Patients With Parkinson's Disease Who Experience Dyskinesia And Motor Fluctuations
A randomized, double blind, placebo-controlled study employing a mixed parallel group and fixed sequence cross-over design. Patients will be randomized to one of two treatment groups ('E2007' or 'Placebo') in a 1:1 ratio and…
- Trial name
- NCT00451633
- Testing
- E2007
- Where
- 5 sites in Germany, Italy
- Sponsor
- Eisai Inc.
Parkinson's Disease
Post Market (Libra/LibraXP System) Deep Brain Stimulation (DBS) Parkinson's Disease Study
The objective of this study is to evaluate the effectiveness of Deep Brain Stimulation as an adjunctive treatment for reducing some of the symptoms of advanced, levodopa-responsive Parkinson's disease that are not adequately…
- Trial name
- NCT01352819
- Where
- 6 sites in France, Germany and 1 more
- Volunteers
- 21 people
- Sponsor
- Abbott Medical Devices
Parkinson's Disease (PD)
Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide
To investigate the effect of three single oral doses of BIA 9-1067 (25 mg, 50 mg and 100 mg) on the levodopa pharmacokinetics when administered in combination with a single-dose of controlled-release levodopa 100 mg/benserazide…
- Trial name
- NCT02169466
- Testing
- BIA 9-1067, Madopar® HBS
- Where
- Portugal
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson's Disease
Phase 2 Clinical Study of KW-6500 in Parkinson's Disease Patients With Motor Response Complication on Levodopa Therapy
The purpose of this study is to evaluate the efficacy of KW-6500 versus placebo when administered as a subcutaneous injection at the individualized maintenance dose level in an OFF state in Parkinson's disease patients with motor…
- Trial name
- NCT00610103
- Testing
- apomorphine hydrochloride
- Where
- 4 sites in Japan
- Volunteers
- 16 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Parkinson Disease
Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia
Mesdopetam (IRL790) is an experimental small molecule compound with psychomotor stabilizing properties. The primary target is the dopamine D3 receptor, a target implicated in the generation of levodopa-induced dyskinesia, a…
- Trial name
- NCT03368170
- Testing
- Mesdopetam (IRL790)
- Where
- 20 sites in Sweden, United Kingdom
- Volunteers
- 75 people
- Sponsor
- Integrative Research Laboratories AB
Pharmacokinetics
Pharmacokinetic Study With Repeated Doses of Stalevo
The purpose of this study is to show that higher minimum concentration values are obtained following repeated doses of Stalevo 4 times daily compared to lecodopa/carbidopa treatment with corresponding dosing regimen.
- Trial name
- NCT00693862
- Testing
- levodopa, carbidopa, entacapone, levodopa, carbidopa
- Where
- 3 sites in Finland
- Volunteers
- 19 people
- Sponsor
- Orion Corporation, Orion Pharma